Endurant Capital Management’s Ocular Therapeutix OCUL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-353,707
| Closed | -$1.11M | – | 44 |
|
|
2023
Q3 | $1.11M | Sell |
353,707
-14,731
| -4% | -$46.3K | 1% | 29 |
|
|
2023
Q2 | $1.9M | Sell |
368,438
-144,306
| -28% | -$745K | 1.66% | 17 |
|
|
2023
Q1 | $2.7M | Sell |
512,744
-551,209
| -52% | -$2.9M | 1.39% | 19 |
|
|
2022
Q4 | $2.99M | Sell |
1,063,953
-342
| -0% | -$961 | 1.21% | 20 |
|
|
2022
Q3 | $4.42M | Buy |
1,064,295
+304,067
| +40% | +$1.26M | 1.44% | 22 |
|
|
2022
Q2 | $3.06M | Sell |
760,228
-163,735
| -18% | -$658K | 1.07% | 22 |
|
|
2022
Q1 | $4.57M | Buy |
923,963
+206,820
| +29% | +$1.02M | 1.2% | 21 |
|
|
2021
Q4 | $5M | Buy |
717,143
+106,742
| +17% | +$744K | 1.21% | 25 |
|
|
2021
Q3 | $6.1M | Buy |
610,401
+39,431
| +7% | +$394K | 1.39% | 21 |
|
|
2021
Q2 | $8.1M | Buy |
570,970
+132,037
| +30% | +$1.87M | 2.23% | 12 |
|
|
2021
Q1 | $7.2M | Buy |
438,933
+148,468
| +51% | +$2.44M | 1.88% | 23 |
|
|
2020
Q4 | $6.01M | Sell |
290,465
-546,672
| -65% | -$11.3M | 2.17% | 17 |
|
|
2020
Q3 | $6.37M | Buy |
837,137
+81,807
| +11% | +$623K | 1.88% | 13 |
|
|
2020
Q2 | $6.29M | Buy |
+755,330
| New | +$6.29M | 0.35% | 14 |
|
|
2019
Q2 | – | Sell |
-716,124
| Closed | -$2.84M | – | 70 |
|
|
2019
Q1 | $2.84M | Buy |
716,124
+483,397
| +208% | +$1.92M | 1.12% | 25 |
|
|
2018
Q4 | $926K | Sell |
232,727
-69,426
| -23% | -$276K | 0.49% | 37 |
|
|
2018
Q3 | $2.08M | Buy |
302,153
+159,378
| +112% | +$1.1M | 0.92% | 32 |
|
|
2018
Q2 | $964K | Sell |
142,775
-35,686
| -20% | -$241K | 0.42% | 45 |
|
|
2018
Q1 | $1.16M | Buy |
+178,461
| New | +$1.16M | 0.43% | 52 |
|